eligibility_summary
Adults ≥18. Group A: unresectable/metastatic solid tumors incl. TNBC, lung adeno, ovarian, pancreas, colorectal, gastric, prostate, bladder, uterus, no effective/tolerable standard therapy, measurable (RECIST 1.1). Group B: R/R CLL/SLL, MCL, DLBCL, measurable disease or CLL PB B cells ≥5e9/L. Archival ≤2y or fresh biopsy, ECOG 0–1, adequate organs, recovered AEs. Exclude prior ROR1, severe irAEs, primary/symptomatic CNS, recent therapy (<5 HL or <4 wks), substance abuse.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05607498 tests EMB-07, an intravenous MAT-Fab bispecific T‑cell–engaging antibody that binds CD3 on T cells and ROR1 on tumor cells. Mechanism: co-binding CD3 and ROR1 activates and redirects cytotoxic T lymphocytes to ROR1+ cancers, inducing TCR/CD3 signaling and T cell–mediated killing (perforin/granzyme). Indications: adults with locally advanced/metastatic solid tumors or relapsed/refractory B‑cell lymphomas (CLL/SLL, MCL, DLBCL). Targets/pathways: CD3 on T cells (TCR activation) and ROR1 (a receptor tyrosine kinase–like orphan receptor overexpressed on malignant cells). Phase 1 dose escalation (weekly IV) to assess safety, MTD/RP2D, PK/PD, immunogenicity, and preliminary antitumor activity.